Related references
Note: Only part of the references are listed.Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Lipid nanoparticles for oral delivery of raloxifene: Optimization, stability, in vivo evaluation and uptake mechanism
Punna Rao Ravi et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation
N. Aditya et al.
JOURNAL OF MICROENCAPSULATION (2014)
Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells
Margherita Piccolella et al.
PHARMACOLOGICAL RESEARCH (2014)
A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
Sebastien Taurin et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles
Madhu Burra et al.
ADVANCED POWDER TECHNOLOGY (2013)
Characterization of Raloxifene Glucuronidation: Potential Role of UGT1A8 Genotype on Raloxifene Metabolism In Vivo
Dongxiao Sun et al.
CANCER PREVENTION RESEARCH (2013)
Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent
Tuan Hiep Tran et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Sebastien Taurin et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene
Tina Trdan Lusin et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment
Tina Trdan Lusin et al.
TRANSLATIONAL RESEARCH (2012)
Prostate cancer epidemiology in the United States
Otis W. Brawley
WORLD JOURNAL OF UROLOGY (2012)
Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin
Nate Larson et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
In vitro evaluation, biodistribution in rats of radiolabeled raloxifene
Elif Bayrak et al.
APPLIED RADIATION AND ISOTOPES (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Ian M. Thompson et al.
JOURNAL OF UROLOGY (2009)
Novel Biodegradable Polyesters. Synthesis and Application as Drug Carriers for the Preparation of Raloxifene HCl Loaded Nanoparticles
Dimitrios Bikiaris et al.
MOLECULES (2009)
Expression of Multidrug Resistance Proteins in Prostate Cancer Is Related With Cell Sensitivity to Chemotherapeutic Drugs
Catherine Sanchez et al.
PROSTATE (2009)
Prostate cancer and metastasis initiating stem cells
Kathleen Kelly et al.
CELL RESEARCH (2008)
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer
Akinobu Hamada et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling
William A. Ricke et al.
FASEB JOURNAL (2008)
Pharmacokinetics of raloxifene in male Wistar-Hannover rats: Influence of complexation with hydroxybutenyl-beta-cyclodextrin
Michael F. Wempe et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
The 44-kDa pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells
Yingqiu Xie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The determination of raloxifene in rat tissue using HPLC
Zhaoyong Yang et al.
BIOMEDICAL CHROMATOGRAPHY (2007)
Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management
Amitava Dasgupta
CLINICA CHIMICA ACTA (2007)
Raloxifene, an oestrogen-receptor-β-targeted therapy, inhibits androgen-independent prostate cancer growth:: results from preclinical studies and a pilot phase II clinical trial
RL Shazer et al.
BJU INTERNATIONAL (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Copoly(styrene-maleic acid) - Pirarubicin micelles: High tumor-targeting efficiency with little toxicity
K Greish et al.
BIOCONJUGATE CHEMISTRY (2005)
Disposition mechanisms of raloxifene in the human intestinal Caco-2 model
EJ Jeong et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours
K Greish et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Role of estrogens in development of prostate cancer
PL Härkönen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2004)
Androgens and prostate cancer
AI So et al.
WORLD JOURNAL OF UROLOGY (2003)
Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance
DC Kemp et al.
DRUG METABOLISM AND DISPOSITION (2002)
Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma
I Leav et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Estrogenic effects on prostatic differentiation and carcinogenesis
GR Cunha et al.
REPRODUCTION FERTILITY AND DEVELOPMENT (2001)
Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies
K Kawai et al.
CANCER LETTERS (2000)
Share Paper
